Takeda, Azurity Unit Sue Turkish Company to Block Edarbi Copies

Takeda Pharmaceutical Co. and Arbor Pharmaceuticals LLC filed a lawsuit in Delaware federal court alleging that a generic version of Edarbi proposed by a unit of Turkey-based EastPharma Ltd. infringes three patents Takeda licenses to Arbor for the drug, used to treat high blood pressure.

Takeda and Arbor filed the complaint March 18 in the U.S. District Court for the District of Delaware against EastPharma’s Saba Ilac Sanayi ve Ticaret AS. NovaQuest Capital’s Azurity Pharmaceuticals acquired Arbor in a deal that closed last October.

Edarbi is an angiotensin II receptor blocker that prevents the narrowing of blood vessels, ...